The global dystrophic epidermolysis bullosa management market is expected to reach USD 452.37 Million in 2023 and is projected to exhibit a CAGR of 5.7% from 2023 to 2033. The high prevalence of skin diseases and the high incidence of dystrophic epidermolysis bullosa management are the major factors driving the global market for dystrophic epidermolysis bullosa management.
Children with RDEB may develop malignant melanoma and adults with EB simplex are at a very high risk of basal cell carcinoma. Patient-centered approach to treating EB is expected to further grow in the market. In order for a plan to be tailored to each individual patient, healthcare professionals use preventative measures, nutritional support, and wound care treatments. In addition to monitoring and updating the patient's treatment plan, assessment of skin lesions and general health tools are expected to grow.
The outcome of antibiotic treatment depends on the infectious status of the wound and the result of an antibiogram. As a result of the recommended strategies, dermatologists will be able to develop individualized care plans for patients with EB. The proposed monitoring instruments can be used to continuously update the treatment plan for the patient, as well as the national recommendations for the management of EB, based on the data provided by the proposed monitoring tools. Further, it may be possible to offer whole exome sequences or targeted panels as part of the next-generation sequencing process. Low cost and rapid turnaround time will be provided by targeted panels that include the testing of commonly found genes with 94.3% efficiency and 75-98 sensitivity.
| Data Points | Key Statistics |
|---|---|
| Estimated Base Year Value (2022) | USD 430 million |
| Expected Market Value (2023) | USD 452.37 million |
| Anticipated Forecast Value (2033) | USD 787.8 million |
| Projected Growth Rate (2023 to 2033) | 5.7% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for dystrophic epidermolysis bullosa management is projected to increase at a CAGR of 5.7% during the forecast period between 2023 and 2033, reaching a total of USD 787.8 Million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.2%.
On the basis of incidence, data show that 50 new cases of epidermolysis bullosa occur every million live births. In 92% of these cases, the epidermolysis bullosa is simplex. In 5% of these cases, the epidermolysis bullosa is dystrophic. In 1% of these cases, it is junctional. Depending on the country and ethnicity, these data may differ significantly. Romanian researchers have identified 72 families with an epidermolysis bullosa variant.
As part of the treatment for the wound, bandages, and dressings that do not adhere to the wound are used to protect it, moisturizers are applied to reduce friction and itching, and pain relievers are prescribed to relieve symptoms. There is a lot of complexity and evolution in the management of dystrophic epidermolysis bullosa. Understanding the underlying cause and mechanisms of the disease is being improved through research into genetics and biology.
The research has opened up new opportunities for developing treatments, including gene therapies and stem cell therapies. Moreover, advances in therapies, nutrition, and pain management will help individuals with dystrophic epidermolysis bullosa to lead a better quality of life. In order to continue improving the lives of those affected, further research into the disease will be explored.
Increased Adoption of Genetic Therapies to Boost Treatment and Care
Growing consumer awareness of DEB and advanced treatments for this disease is expected to boost the market over the next few years. It is anticipated that the number of people suffering from dystrophic epidermolysis bullosa will continue to rise and that innovative treatments will soon be launched to address this disease.
Research and development advances will lead to a global market expansion for dystrophic epidermolysis bullosa treatment over the forecast period. As a result of advancements in gene panels across epidermolysis bullosa centers for treatment, whole-exome sequencing has revolutionized dystrophic epidermolysis bullosa treatment and diagnostics. It is expected that the market is further anticipated to grow due to increasing consumer spending power and economic growth.
As biologics and biosimilars are more effective at treating diseases, the demand for newer, technologically enhanced products is growing in the market. Due to this fact, major players that operate in the field of pharmaceuticals invest in research to come up with new drugs to treat DEB in the market. In the forecast period, key players are expected to invest more in research and development activities.
Scientific Development to Expand the Market for Dystrophic Epidermolysis Bullosa Management
New drugs and technological advances have positively impacted the market for dystrophic epidermolysis bullosa management. In recent years, new drugs and improved diagnosis and treatment protocols have improved treatment efficiency for dystrophic epidermolysis bullosa management infection.
As science has advanced rapidly in recent years, a variety of therapeutic strategies for treating EB now appear to be promising and grow the market. In order to determine priority research areas for the EB community, the scientific and clinical communities are working in close collaboration. In addition to being active and successful in fundraising, many patient advocacy organizations provide funds for the clinical research project as well. Numerous therapies are currently in preclinical development, with the first ones having already advanced to phase 1/2 or 3 clinical trials. In addition to these factors, the market for DEB management is expected to experience strong growth in the coming years.
Principal Consultant
Low Awareness about Diseases and the High Cost of Drugs will Hamper the Market
The limited cure for these diseases is likely to further hamper the market growth in the future. As a result of the high cost of diseases and medications, the growth of the market is expected to be further constrained. A decrease in supportive care for these types of diseases is expected to negatively impact the market. Severe skin fragility can cause significant emotional and physical distress for patients with DEB. Quality of life can be greatly affected by this, which can have a major impact on the market.
As DEB is a rare disorder, there is still a lack of awareness about the condition in many parts of the world. As a result, patients may be unable to receive the appropriate support and care that they require. A survey has demonstrated that epidermolysis bullosa burdens patients, their loved ones, and healthcare professionals. Patients with epidermolysis bullosa and their caregivers must compromise their educational and career goals due to the limitations caused by the disease. Additionally, the financial burden is a significant impact on epidermolysis bullosa in patients.
For instance, the National Center for Biotechnology Information reported on September 8, 2020, that epidermolysis bullosa bandage costs ranged between USD 262 and over USD 2000 per month.
Hospitals that Specialize in Treating Dystrophic Epidermolysis Bullosa to Grow the Market
Globally, North American markets are forecast to account for 23% of the overall market. According to projections, North America will dominate the global market for dystrophic epidermolysis bullosa management. Due to developing healthcare infrastructure, increased grants for rare diseases, and technological advancements.
A study conducted by the USA National Epidermolysis Bullosa Registry indicates that epidermolysis bullosa occurs in 19.6 out of 1 million live births and is prevalent in 11.07 out of 1 million live births. It was estimated that 7.87 cases and six cases were diagnosed per million live births, respectively, for epidermolysis bullosa simplex.
As a result of the presence of a large number of pharmaceutical and biotech companies, coupled with a well-developed healthcare infrastructure, North America is the largest market for the dystrophic epidermolysis bullosa management market. Additionally, there are several other factors that contribute to the growth of the EB market in North America, including the high prevalence of EB in the region, the growth of awareness about EB and its treatment, and the EB-related products and services are supporting the market's growth.
Intense Competition for Rare Disease Treatments Drives Dystrophic Epidermolysis Bullosa Management
Europe is projected to grow at a CAGR of 2.6% during the forecast period. Industry forecasts predict that the European market will grow at the fastest rate in the next few years. The large population of Europe and increasing awareness of dystrophic epidermolysis bullosa make it a desirable market for dystrophic epidermolysis bullosa management. Inflammatory new diseases such as dystrophic epidermolysis bullosa are becoming more prevalent as disposable income and treatment options increase in this region.
The region is also home to some of the world's most advanced healthcare systems, which allow clients to access treatments for rare diseases such as dystrophic epidermolysis bullosa. In addition, the European healthcare system is well-developed and highly funded, which makes it easier for patients suffering from rare diseases such as dystrophic epidermolysis bullosa to get the best available treatment. Moreover, the region is home to several elite companies that specialize in dystrophic epidermolysis bullosa management, and as a result, it is leading innovation and the development of new treatments in the field.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Antibiotics to Boost Dystrophic Epidermolysis Bullosa Management Market Growth
Due to rising research and development and product launches, antibiotics are expected to account for the largest share of the market during the forecast period. Antibiotics are expected to hold a market share of 32% by 2023. Antibiotics are becoming a more common treatment option for DEB, and this will lead to a growing market for DEB management. DEB has become more prevalent as more people are able to access treatments that improve their quality of life.
A rare skin condition characterized by fragile, blistering skin, dystrophic epidermolysis bullosa (DEB), has been found to respond well to antibiotic treatment. In the case of DEB, antibiotics can be used as an effective treatment in order to reduce the risk of bacterial infections that might occur and to treat infections. Aside from this, they can also be used to alleviate inflammation from the condition, reduce the amount of pain associated with it, as well as stop blisters from forming, and reduce the formation of new ones.
Hospital Pharmacies to be the Most Promising Segment for Dystrophic Epidermolysis Bullosa Management Market
Health consciousness and aging populations are projected to drive the hospital pharmacy business. The hospital pharmacy sector is expected to grow at a compound annual growth rate of 3.4% during the forecast period. Pharmacy services, therapies, and medications offered through hospital pharmacies help treat dystrophic epidermolysis bullosa.
Using the latest advances in technological advances, pharmacies are developing and delivering tailored treatment plans based on individual patient needs, tailoring the treatment plan appropriate to the patient's needs. A few of these measures involve giving pharmacists access to debilitating medications specifically formulated to treat DEB, providing information on the best options for treatment, and giving access to pharmacists that are familiar and experienced with treating DEB.
Also, hospitals are working closely with their own development teams to come up with new treatments and therapies to be used for DEB patients that can be adapted to their specific needs through their own research and development. Hospital pharmacies help grow the DEB management market by providing patients with the latest medications and therapies.
Startups in the field of dystrophic epidermolysis bullosa management include the following:
Researchers and developers are developing new products and devices for diagnosis and treatment in the global dystrophic epidermolysis bullosa management market. These new developments are expected to lead to a number of new treatments being launched within the next few years. Companies have a competitive advantage over their competitors when they obtain approval for new products in a timely manner.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 452.37 million |
| Market Value in 2033 | USD 787.8 million |
| Growth Rate | CAGR 5.7% |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Disease Type, Drug Class, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Castle Creek Biosciences; Amryth Pharma; Krystal Biotech; Abeona Therapeutics; BridgeBio; Phoenix Tissue Repair; Wings Therapeutics; InMed Pharmaceuticals, Inc.; Regenerx Biopharmaceuticals Inc.; Holostem Terapie Avanzate S.r.l. |
| Customization | Available Upon Request |
The market is estimated to reach USD 452.37 million in 2023.
Amryth Pharma, Krystal Biotech, and BridgeBio are the key players in the market.
The market is estimated to secure a valuation of USD 787.8 million by 2033.
The growth potential of the market is 5.7% CAGR through 2033
Increased adoption of genetic therapies boosts treatment and care.
1. Executive Summary | Dystrophic Epidermolysis Bullosa Management Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type 5.1. Dominant Dystrophic Epidermolysis Bullosa (DDEB) 5.2. Recessive Dystrophic Epidermolysis Bullosa (RDEB) 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 6.1. Antibiotics 6.2. Corticosteroids 6.3. Opioid Analgesics 6.4. Anticonvulsant 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Retail Pharmacies 7.3. Online Pharmacies 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. Middle East and Africa (MEA) 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Castle Creek Biosciences 18.2. Amryth Pharma 18.3. Krystal Biotech 18.4. Abeona Therapeutics 18.5. BridgeBio 18.6. Phoenix Tissue Repair 18.7. Wings Therapeutics 18.8. InMed Pharmaceuticals, Inc. 18.9. Regenerx Biopharmaceuticals Inc 18.10. Holostem Terapie Avanzate S.r.l. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Dystrophic Epidermolysis Bullosa Management Market
